Gerresheimer AG (0NTI)
London Stock Exchange · UK · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 32.75 |
|---|---|
| 52-week range | 14.98 – 33.31 |
| Return, 1 month / 3 months | +26.3% / +15.6% |
| Return, 1 year / 3 years | +11.9% / −62.6% |
| Trend | Uptrend |
| RSI (14) | 69 |
| Volatility (1 year) | 70.5% |
| Worst drawdown (1 year) | -46.1% |
| Average daily value traded | 0.10M EUR |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Gerresheimer makes glass and plastic packaging and delivery systems for the pharmaceutical, biotech and healthcare industries. Its products include vials, ampoules, syringes, cartridges and insulin pens, along with plastic containers and closures for medicines and cosmetics. Customers are mainly drug makers and healthcare companies that need primary packaging and drug delivery devices. The company is based in Düsseldorf, Germany, and supplies customers in Europe, the Americas and Asia.
Gerresheimer AG trades under the code 0NTI on the London Stock Exchange in UK, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 7 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Gerresheimer AG (0NTI) trades on the London Stock Exchange in UK. It last closed at EUR 32.75 on 27 October 2026.
Its price-based Market X-Ray is 54 out of 100 (a fair price profile), ranking 1,796 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 11.9% and over the last three months it rose 15.6%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 90 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 30.1% | ||
| From 52-week high | -1.7% | ||
| Momentum | 68 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 15.6% | ||
| 6-month return | 36.3% | ||
| 12-month return, skipping the last month | -11.4% | ||
| Stability (higher is calmer) | 19 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 70.5% | ||
| Worst drawdown, 1 year (smaller is calmer) | -46.1% | ||
| Liquidity | 30 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.10M EUR | ||
| Zero-volume days | 1.7% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 4 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
Weak spots
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | +1.3% |
|---|---|
| 1 month | +26.3% |
| 3 months | +15.6% |
| 6 months | +36.3% |
| 1 year | +11.9% |
| 3 years | −62.6% |
| 5 years | −57.1% |
Signals
| 50-day / 200-day average | 28.46 / 25.18 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 2.49 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 6 Jun 2025 | EUR 0.0400 |
| 6 Jun 2024 | EUR 1.2500 |
| 8 Jun 2023 | EUR 1.2500 |
| 9 Jun 2022 | EUR 1.2500 |
| 10 Jun 2021 | EUR 1.2500 |
| 25 Jun 2020 | EUR 1.2000 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.